Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03141034 · ClinicalTrials.gov registry record · Phase 2
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03141034 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT03141034, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The investigators hypothesize that this combination regimen of irinotecan plus ramucirumab administered as second line treatment will be tolerated and lead to improved outcomes similar to paclitaxel plus ramucirumab in patients with advanced gastric and gastro-esophageal junction (GEJ) cancers. This study proposes a phase II clinical trial with irinotecan plus ramucirumab for treatment of patients with metastatic gastric and GEJ adenocarcinoma who have progressed after first line chemotherapy. To the knowledge of the investigators, this regimen has not been previously administered to this patient population, so safety and tolerability will be monitored and reported.
Interventions
- DRUG Irinotecan
- DRUG Ramucirumab
- GENETIC Blood for angiome profiling
- GENETIC Blood for cfDNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03141034
The ClinicalTrials.gov registry entry for NCT03141034 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Irinotecan is the first listed.
NCT03141034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03141034 about?
NCT03141034 is a clinical study titled "Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma". The investigators hypothesize that this combination regimen of irinotecan plus ramucirumab administered as second line treatment will be tolerated and lead to improved outcomes similar to paclitaxel plus ramucirumab in patients with advanced gastric and gastro-esophageal junction (GEJ) cancers. This...
What is the current status of trial NCT03141034?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-11-01. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT03141034?
The interventions under investigation include: Irinotecan (DRUG), Ramucirumab (DRUG), Blood for angiome profiling (GENETIC), Blood for cfDNA (GENETIC).
Who is sponsoring clinical trial NCT03141034?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.